<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121057">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01950871</url>
  </required_header>
  <id_info>
    <org_study_id>CR2P01127</org_study_id>
    <secondary_id>DRKS00005263</secondary_id>
    <nct_id>NCT01950871</nct_id>
  </id_info>
  <brief_title>Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate HistoScanning</brief_title>
  <acronym>PHSTT-01</acronym>
  <official_title>Diagnostic Performance of Prostate HistoScanningTM (PHS) in Men at Risk of Prostate Cancer Scheduled for an Initial Prostate Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Advanced Medical Diagnostics s.a.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Advanced Medical Diagnostics s.a.</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
    <authority>Belgium: Ethics Committee</authority>
    <authority>Bulgaria: Ethics committee</authority>
    <authority>Czech Republic: Ethics Committee</authority>
    <authority>Denmark: Ethics Committee</authority>
    <authority>Estonia: Research Ethics Committee</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Hungary: Research Ethics Medical Committee</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Latvia: Institutional Review Board</authority>
    <authority>Lithuania: Bioethics Committee</authority>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <authority>Russia: Ethics Committee</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>Switzerland: Ethikkommission</authority>
    <authority>Turkey: Ethics Committee</authority>
    <authority>United Kingdom: National Health Service</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the PHSTT-01 trial is to determine if prostate HistoScanning (HS)
      analysis can be used to improve the detection of clinically significant prostate cancer
      (PCa), and potentially reduce the burden and number of biopsies in routine clinical
      practice. Prostate HS is an ultrasound-based tissue characterization technology specifically
      developed to detect, visualize, and locate tissue suspected of harboring PCa. These
      suspicious tissues are displayed as red areas on an imaging monitor. Recently a new biopsy
      guidance tool has been developed that uses the results of the prostate HS analysis.

      The subjects that will participate in this study are all scheduled for a first biopsy of the
      prostate. They will initially be imaged using transrectal ultrasound (TRUS) to obtain data
      for prostate HS analysis. The results of HS analysis will be used later in the procedure.
      Subjects will then undergo a routine systematic 10- to 12-core biopsy procedure using TRUS.
      This will be followed by a TRUS-guided biopsy that uses the result of prostate HS analysis
      and new biopsy guidance tool.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PHSTT-01 is a multi-center, prospective clinical trial to evaluate the diagnostic
      performance of prostate HistoScanning (HS) analysis in men at risk of PCa that have been
      scheduled for a first prostate biopsy. The purpose of this study is to determine if prostate
      HS analysis can improve the detection of clinically significant PCa, and potentially reduce
      the burden and number of biopsies in routine clinical practice. Subjects are men with serum
      total prostate-specific antigen (PCA) &lt;= 20ng/mL (&lt;= 10ng/mL if taking the 5-alpha reductase
      inhibitor).

      In a single visit, subjects will first be imaged with TRUS for the purpose of generating
      data for prostate HS analysis. The results of HS analysis will be used later in the
      procedure. Subjects will then undergo two consecutive biopsy procedures. First, using TRUS,
      a systematic 10- to 12-core biopsy procedure will be performed. In turn, prostate HS data
      taken at the beginning of the procedure will be used to determine suspicious areas
      (displayed as red on an imaging monitor) and used to guide the biopsy procedure. Areas that
      are identified as suspicious (zero to a maximum of 3 areas) will then be sampled with two
      biopsy cores. Depending on the number of suspicious areas identified by prostate HS, the
      number of cores will be zero to a maximum of 6 cores.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Diagnostic performance of prostate HistoScanning (HS) to identify clinically significant PCa using histology outcomes from systematic prostate biopsy (Bx) as reference</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare prostate HS results to the systematic Bx outcome (positive or negative) for clinically significant PCa (defined as Gleason sum ≥ 7) in the non-run-in population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance of prostate HS to identify PCa using histology outcomes from systematic Bx as reference</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare prostate HS results to the systematic Bx outcome (positive or negative) for all PCa in the non-run-in population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance of prostate HS to identify clinically significant PCa using a combination of outcomes of both systematic Bx and HS-guided biopsy histology as reference</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare prostate HS results to the combination of systematic and HS-guided Bx outcomes (positive or negative) for clinically significant PCa (defined as Gleason sum ≥ 7) in the non-run-in population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in detection rates of clinically significant PCa between systematic and HS-guided biopsy.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compared PCa detection rates of systematic and HS-guided prostate Bx in the non-run-in population.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">391</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>single arm study</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Prostate HistoScanning (HS) analysis with HS-guided biopsy will be used to sample two cores per suspicious area (displayed as red on an imaging monitor), up to a maximum of 3 suspicious areas per subject. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero (if no suspicious area is identified) up to a maximum of 6 cores.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prostate HistoScanning</intervention_name>
    <description>In a single visit, subjects will first be imaged with TRUS for the purpose of generating data for prostate HS analysis. The results of HS analysis will be used later in the procedure. Subjects will then undergo two consecutive biopsy procedures. First, using TRUS, a systematic 10- to 12-core biopsy procedure will be performed. In turn, prostate HS data taken at the beginning of the procedure will be used to determine suspicious areas (displayed as red on an imaging monitor) and used to guide the biopsy procedure. Areas that are identified as suspicious (zero to a maximum of 3 areas) will then be sampled with two biopsy cores. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero to a maximum of 6 cores.</description>
    <arm_group_label>single arm study</arm_group_label>
    <other_name>PHS/PHS TT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men at risk of PCa scheduled for first biopsy with serum total PSA

             ≤ 20 ng/ml (≤ 10 ng/mL if taking 5-alpha reductase inhibitors) from maximally 3
             months ago

          -  Signed informed consent

        Exclusion Criteria:

          -  Previous prostate biopsy

          -  Confirmed PCa

          -  PSA &gt; 20 ng/ml (or &gt; 10 ng/mL if taking 5-alpha reductase inhibitors)

          -  Active urinary tract infection

          -  Presence/history of any confirmed cancer

          -  Recent prostatic surgery (past 6 months)

          -  History of pelvic radiotherapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand Tombal, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires Saint-Luc, Brussels, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie MY Danloy, MSc</last_name>
    <phone>+32 (0)2 352 80 30</phone>
    <email>clinical@histoscanning.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Center Hanuschkrankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andreas Lunacek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder</name>
      <address>
        <city>Vienna</city>
        <zip>1020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Franz Bliem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Med.Landeskrankenhaus Vöcklabruck</name>
      <address>
        <city>Vöcklabruck</city>
        <zip>4840</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael Dunzinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Onze Lieve Vrouw Ziekenhuis OLVZ</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alexandre Mottrie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>• University Medical Center Cliniques Universitaires Saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bertrand Tombal, MD, Prof</last_name>
      <phone>+32 2 7641415</phone>
      <email>bertrand.tombal@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Bertrand Tombal, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center UZ VUB</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johan Braeckman, MD, PhD</last_name>
      <phone>+32 2 477 6307</phone>
      <email>Johan.Braeckman@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Johan Braeckman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center St. Marina University Hospital</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alexander Hinev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Urologická klinika - Fakultní nemocnice</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>František Zatura, Prof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Všeobecná fakultní nemocnice v Praze (VFN) a 1. -General University Hospital and First Faculty of Medicine Charles University</name>
      <address>
        <city>Praha</city>
        <zip>15006</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Petr Macek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>• University Medical Center Urinary Tract Surgery - Urology Dpt - Odense Universitetshospital Svendborg Sygehus</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lars Lund, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center North-Estonian Medical Center Foundation</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Leonhard Kukk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Institut Mutualiste Montouris</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rafael Sanchez-Salas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center CHU Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas Mottet Auselo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Cancer Center - Prostatazentrum</name>
      <address>
        <city>Braunschweig</city>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lukas Manka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Paracelsus Klinik</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40474</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Bastian, MD</last_name>
      <phone>+49 (0) 211 - 43 86 - 101</phone>
    </contact>
    <investigator>
      <last_name>Patrick Bastian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Martini Klinik - Prostate Cancer Center</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Georg Salomon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Klinikum Herford</name>
      <address>
        <city>Herford</city>
        <zip>32049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathrin Stäube</last_name>
    </contact>
    <investigator>
      <last_name>Klaus Jürgen Weichert-Jacobsen, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center PAN Klinik</name>
      <address>
        <city>Köln</city>
        <zip>50667</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Berges, MD</last_name>
      <phone>+49 (0) 211 - 43 86</phone>
      <email>duesseldorf@pk-mx.de</email>
    </contact>
    <investigator>
      <last_name>Richard Berges, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center St. Elisabeth Krankenhaus</name>
      <address>
        <city>Leipzig</city>
        <zip>04277</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Hainich</last_name>
      <phone>+ 49 (0) 341 3959 7456</phone>
      <email>susanne.hainich@ek-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Jöerg Rassler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Klinikum Leverkusen</name>
      <address>
        <city>Leverkusen</city>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tobias Kowalke, MD</last_name>
      <phone>+49 4 515 002 896</phone>
    </contact>
    <investigator>
      <last_name>Jürgen Zumbe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Klinikum Wolfsburg Urologie</name>
      <address>
        <city>Wolfsburg</city>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Sotelino, MD</last_name>
      <phone>+49 5361 80-3762</phone>
      <email>petra.labodt-mrozek@klinikum.wolfsburg.de</email>
    </contact>
    <investigator>
      <last_name>Armin Leitenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Uro-Clin Ltd</name>
      <address>
        <city>Pécs</city>
        <zip>7601 Pf. 246</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tamás Benko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center University Vita-Salute, Scientific Institute H. San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vincenzo C Scattoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center URO</name>
      <address>
        <city>Riga</city>
        <zip>1006</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Atis Karulis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Vilniaus Universiteto Onkologijos Institutas - Santariškiu Clinics</name>
      <address>
        <city>Vilnius</city>
        <zip>08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Albertas Ukys, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Antoni Van Leeuwenhoek Ziekenhuis - Nederlands Kanker Instituut</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Henk van der Poel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Moscow State University of Medicine and Dentistry named after A.I.Evdokimov</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alexander Govorov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Vall d'Hebron University Hospital - Autonoma Universitat Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Juan Morote Robles, Prof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carouge medical centre</name>
      <address>
        <city>Carouge</city>
        <zip>1227</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Regusci, MD</last_name>
      <phone>+41 22 343 92 12</phone>
      <email>cabinetregusci@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Stefano Regusci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center URO-TIP Urological Diagnosis Center</name>
      <address>
        <city>Istanbul</city>
        <zip>34740</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ibrahim Cevik, Prof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Acıbadem Kozyatağı Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34742</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Håkan Ozveri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Blackpool Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <zip>FY38NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Neil James Peter Rothwell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Nuffield Health - University Hospitals Bristol (UHB) - Bristol Royal Infirmary and Southmead Hospitals</name>
      <address>
        <city>Bristol</city>
        <zip>BS28HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Persad Rajendra, Prof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center Spire Washington Hospital</name>
      <address>
        <city>Tyne and Wear</city>
        <zip>NE38 9JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Damien Greene, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://drks-neu.uniklinik-freiburg.de/drks_web/</url>
    <description>Deutsche Register für klinische Studien (DRKS)</description>
  </link>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 3, 2014</lastchanged_date>
  <firstreceived_date>September 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HistoScanning</keyword>
  <keyword>TRUS</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Biopsy guidance</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
